Vitiligo with new lesions or extension of old lesions during the last 6 months
Conditions
Brief summary
Evaluation of reduction in the VASI score in the experimental group receiving MTX + UVB TL01 assessed 8 months after the start of treatment.
Detailed description
Evaluation of VASI score reduction at M4, Evaluation of clinical and biological measures of MTX and phototherapy safety at M4 and M8, Evaluation of VETF score variation, Evaluation of F-VASI score variation, Evaluation of F-VASI score variation, Evaluation of variation in the DLQI (Dermatology Quality of Life Index) score, Assessment of variations in blood and skin inflammatory parameters: ELISA on serum at baseline, M2, M4 and M8
Interventions
DRUGMICROCRYSTALLINE CELLULOSE
DRUGMETHOTREXATE
DRUGFOLIC ACID
Sponsors
Centre Hospitalier Universitaire De Bordeaux
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of reduction in the VASI score in the experimental group receiving MTX + UVB TL01 assessed 8 months after the start of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of VASI score reduction at M4, Evaluation of clinical and biological measures of MTX and phototherapy safety at M4 and M8, Evaluation of VETF score variation, Evaluation of F-VASI score variation, Evaluation of F-VASI score variation, Evaluation of variation in the DLQI (Dermatology Quality of Life Index) score, Assessment of variations in blood and skin inflammatory parameters: ELISA on serum at baseline, M2, M4 and M8 | — |
Countries
France
Outcome results
None listed